文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

COVID-19重症患者的急性肾损伤

Acute kidney injury in critically ill patients with COVID-19.
PubMed 文献 · Intensive Care Med · 2020-06-12
一句话结论COVID-19重症患者急性肾损伤发生率高达25%,与高死亡率相关,需肾替代治疗者尤甚;目前无特异性治疗,肾替代治疗指征与时机沿用脓毒症非特异性数据。

本文综述了COVID-19重症患者急性肾损伤(AKI)的流行病学、病理生理机制及管理现状。AKI在重症SARS-CoV-2感染患者中报告率高达25%,尤其见于有基础合并症者,且与高死亡率相关,需要肾替代治疗时尤为显著。研究提示尿液SARS-CoV-2排泄及肾小管受体ACE2高表达,可能介导直接细胞损伤;非特异性机制包括血流动力学改变、右心衰竭、高PEEP、低血容量、肾毒性药物及院内脓毒症。目前无特异性治疗,肾替代治疗的指征、时机和模式依赖脓毒症的非特异性数据,亟需进一步研究。

要点

  • 重症COVID-19患者AKI报告率高达25%,尤其见于有基础合并症者,需要肾替代治疗时死亡率高。
  • 尿液检查可见蛋白尿和血尿,并有证据显示尿液SARS-CoV-2排泄,提示肾脏可能是病毒储库。
  • 病理生理机制包括病毒经ACE2直接损伤肾细胞、肾素-血管紧张素-醛固酮系统失衡、炎症细胞因子及血栓事件。
  • 非特异性机制包括血流动力学改变、右心衰竭、机械通气高PEEP、低血容量、肾毒性药物及院内脓毒症。
  • 目前无COVID-19所致AKI的特异性治疗;肾替代治疗的指征、时机和模式依赖脓毒症的非特异性数据。

适用人群与场景

  • 重症SARS-CoV-2感染患者,尤其是有基础合并症者。

处置流程与药物剂量

  • 目前无COVID-19所致AKI的特异性治疗;多种研究性抗病毒/免疫调节药物正在探索中,其对AKI的影响尚不清楚。
  • 肾替代治疗的指征、时机和模式目前依赖针对脓毒症患者的非特异性数据。

研究设计与关键结果

  • 综述指出重症COVID-19患者AKI报告率高达25%,尤其见于有基础合并症者;AKI与高死亡率相关,需要肾替代治疗时尤为显著。
  • 研究强调尿液沉渣改变包括蛋白尿和血尿,并有证据显示尿液SARS-CoV-2排泄,提示肾脏可能是病毒储库。
  • 病理生理机制涉及病毒经ACE2直接细胞损伤、肾素-血管紧张素-醛固酮系统失衡、病毒感染引发的促炎细胞因子及血栓事件;非特异性机制包括血流动力学改变、右心衰竭、机械通气高PEEP、低血容量、肾毒性药物及院内脓毒症。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对重症COVID-19患者应监测肾功能及尿液沉渣(蛋白尿、血尿),尤其是有基础合并症者。
  • 肾替代治疗的指征、时机和模式目前参考脓毒症的非特异性数据,尚无COVID-19特异性证据。
  • 研究性抗病毒/免疫调节药物对AKI的影响尚不清楚,使用时应关注肾功能。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Acute kidney injury (AKI) has been reported in up to 25% of critically-ill patients with SARS-CoV-2 infection, especially in those with underlying comorbidities. AKI is associated with high mortality rates in this setting, especially when renal replacement therapy is required. Several studies have highlighted changes in urinary sediment, including proteinuria and hematuria, and evidence of urinary SARS-CoV-2 excretion, suggesting the presence of a renal reservoir for the virus. The pathophysiology of COVID-19 associated AKI could be related to unspecific mechanisms but also to COVID-specific mechanisms such as direct cellular injury resulting from viral entry through the receptor (ACE2) which is highly expressed in the kidney, an imbalanced renin-angotensin-aldosteron system, pro-inflammatory cytokines elicited by the viral infection and thrombotic events. Non-specific mechanisms include haemodynamic alterations, right heart failure, high levels of PEEP in patients requiring mechanical ventilation, hypovolemia, administration of nephrotoxic drugs and nosocomial sepsis. To date, there is no specific treatment for COVID-19 induced AKI. A number of investigational agents are being explored for antiviral/immunomodulatory treatment of COVID-19 and their impact on AKI is still unknown. Indications, timing and modalities of renal replacement therapy currently rely on non-specific data focusing on patients with sepsis. Further studies focusing on AKI in COVID-19 patients are urgently warranted in order to predict the risk of AKI, to identify the exact mechanisms of renal injury and to suggest targeted interventions.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Gabarre P, Dumas G, Dupont T, et al. Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med. 2020. PMID: 32533197. doi:10.1007/s00134-020-06153-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。